公司資料
Lucid Diagnostics 股價、新聞與催化劑
- 股票代碼:
- LUCD
- 交易所:
- NASDAQ
- 產業:
- MedTech
- 所在地:
- United States
股票表現
0.96 USD (+0.41%)
收盤價
最後更新: 2026年8月21日
196M USD
市值
股價為何變動
As of Aug 21, 2026, LUCD closed up 0.41% at $0.9643. No new same-company headline was identified in the current news window.
公司概覽
Esophageal Cancer Prevention Company
Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease.
EsoGuard and EsoCheck
The EsoGuard DNA test is performed on samples collected with the non-endoscopic EsoCheck cell-collection device. Together, the products are designed to identify at-risk patients before esophageal cancer develops.
Commercial and Reimbursement Model
Lucid generates revenue from processed EsoGuard tests while building adoption through gastroenterologists, health systems, commercial payers, Medicare, and the Veterans Health Administration.
未來催化劑
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。